Abingworth taps biopharma’s appetite for risk-sharing
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
Takeda spreads it bets in Huntington’s
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Gilead would rather forget filgotinib
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
